Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 2/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | AMD1 | P17707 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165609 | 1.00 | DNPH1 (0.44) | DNPH1SLC29A1ALDH1A1MAPTKDM4E | |
| SCHEMBL15165608 | 0.83 | DNPH1 (0.39) | DNPH1SLC29A1ALDH1A1MAPTKDM4E | |
| SCHEMBL13239691 | 0.83 | DNPH1 (0.39) | DNPH1SLC29A1ALDH1A1MAPTKDM4E | |
| SCHEMBL13265487 | 0.82 | SLC29A1 (0.62) | DNPH1SLC29A1ALDH1A1ADORA1 | |
| SCHEMBL13239677 | 0.77 | SLC29A1 (0.44) | SLC29A1ADORA1GAA | |
| SCHEMBL15165601 | 0.77 | SLC29A1 (0.44) | SLC29A1ADORA1GAA | |
| SCHEMBL13265435 | 0.75 | ALDH1A1 (0.46) | DNPH1SLC29A1ALDH1A1MAPT | |
| SCHEMBL13239688 | 0.75 | SLC29A1 (0.46) | SLC29A1 | |
| SCHEMBL15165605 | 0.75 | SLC29A1 (0.46) | SLC29A1 | |
| SCHEMBL15165611 | 0.75 | DNPH1 (0.40) | DNPH1SLC29A1ADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | DNPH1 121/4885SLC29A1 19/4885ALDH1A1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.